TEVIMBRA
Drug
BeiGene, Ltd.
Total Payments
$7.0M
Transactions
2,570
Doctors
759
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $7.0M | 2,570 | 759 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.8M | 1,728 | 97.2% |
| Consulting Fee | $163,870 | 75 | 2.3% |
| Food and Beverage | $17,906 | 752 | 0.3% |
| Travel and Lodging | $15,428 | 15 | 0.2% |
Payments by Type
Research
$6.8M
1,728 transactions
General
$197,203
842 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | BeiGene, Ltd. | $1.8M | 0 |
| A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors | BeiGene, Ltd. | $978,352 | 0 |
| A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | BeiGene, Ltd. | $909,139 | 0 |
| Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | BeiGene, Ltd. | $591,965 | 0 |
| A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | BeiGene USA, Inc. | $452,238 | 0 |
| AdvanTIG-205 | BeiGene, Ltd. | $413,162 | 0 |
| A Randomized, Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination with Investigational Agents as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | BeiGene, Ltd. | $298,865 | 0 |
| Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-B167, A Carcinoembryonic Antigen (CEA) Targeted 4-1BB (CD137) Bi-specific Agonistic Antibody, Alone and in Combination With Tislelizumab in Patients With Selected Advanced Solid Tumors | BeiGene, Ltd. | $239,384 | 0 |
| A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors | BeiGene, Ltd. | $220,559 | 0 |
| A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors | BeiGene, Ltd. | $193,092 | 0 |
| A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) | BeiGene, Ltd. | $184,899 | 0 |
| A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 Versus Sorafenib as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma | BeiGene, Ltd. | $117,663 | 0 |
| A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) | BeiGene USA, Inc. | $113,991 | 0 |
| Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | BeiGene, Ltd. | $75,000 | 0 |
| An Open-Label, Multicenter, Long-term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies | BeiGene, Ltd. | $60,165 | 0 |
| A Phase 1a/1b study investigating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity BGB-A538, alone and in combination with Tislelizumab with or without Ociperlimab In patients with selected advanced or metastatic solid tumors | BeiGene USA, Inc. | $45,890 | 0 |
| A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) plus Platinum and Fluoropyrimidine Versus Placebo plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction | BeiGene, Ltd. | $15,914 | 0 |
| A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma | BeiGene, Ltd. | $14,194 | 0 |
| A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with Chemotherapy as First-Line Treatment in Patients with Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | BeiGene, Ltd. | $12,250 | 0 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Patients With Localized Esophageal Squamous Cell Carcinoma | BeiGene, Ltd. | $5,060 | 0 |
Top Doctors Receiving Payments for TEVIMBRA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Minneapolis, MN | $6.8M | 1,728 |
| , M.D | Hematology | Los Angeles, CA | $11,151 | 3 |
| , MD | Medical Oncology | New York, NY | $10,232 | 4 |
| , MD | Hematology | New Haven, CT | $8,069 | 6 |
| , DR | Medical Oncology | Boston, MA | $8,042 | 5 |
| Sarbajit Mukherjee | Medical Oncology | Buffalo, NY | $7,667 | 5 |
| , M.D | Internal Medicine | Houston, TX | $5,250 | 1 |
| , MD | Internal Medicine | New Haven, CT | $5,102 | 3 |
| , MD | Medical Oncology | Bronx, NY | $5,094 | 4 |
| , M.D | Internal Medicine | Houston, TX | $4,500 | 1 |
| , MD | Hematology & Oncology | New Brunswick, NJ | $4,017 | 4 |
| , MD | Internal Medicine | Santa Monica, CA | $3,750 | 1 |
| , M.D. PHD | Internal Medicine | Nashville, TN | $3,375 | 1 |
| , MD | Internal Medicine | Dallas, TX | $3,375 | 2 |
| , M.D | Hematology & Oncology | Rochester, MN | $3,375 | 1 |
| , M.D | Internal Medicine | Los Angeles, CA | $3,375 | 1 |
| , MD, MPH | Medical Oncology | New York, NY | $2,700 | 2 |
| , M.D | Hematology & Oncology | Scottsdale, AZ | $2,625 | 1 |
| , MD | Hematology | Detroit, MI | $2,625 | 1 |
| , MD | Internal Medicine | Durham, NC | $2,625 | 1 |
| , MD | Medical Oncology | New York, NY | $2,625 | 1 |
| , MD | Medical Oncology | New Haven, CT | $2,625 | 1 |
| , MD | Hematology & Oncology | New York, NY | $2,408 | 3 |
| , MD, MS | Hematology | Irvine, CA | $2,357 | 2 |
| , M.D | Hematology | New Haven, CT | $2,250 | 1 |
Ad
Manufacturing Companies
- BeiGene, Ltd. $6.2M
- BeiGene USA, Inc. $807,822
- BeiGene Switzerland GmbH $1,500
Product Information
- Type Drug
- Total Payments $7.0M
- Total Doctors 759
- Transactions 2,570
About TEVIMBRA
TEVIMBRA is a drug associated with $7.0M in payments to 759 healthcare providers, recorded across 2,570 transactions in the CMS Open Payments database. The primary manufacturer is BeiGene, Ltd..
Payment data is available from 2024 to 2024. In 2024, $7.0M was paid across 2,570 transactions to 759 doctors.
The most common payment nature for TEVIMBRA is "Unspecified" ($6.8M, 97.2% of total).
TEVIMBRA is associated with 20 research studies, including "A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer" ($1.8M).